Gout as a risk factor for osteoporosis: epidemiologic evidence from a population-based longitudinal study involving 108,060 individuals

作者: V. C. Kok , J.-T. Horng , M. N. Wang , Z.-Y. Chen , J.-T. Kuo

DOI: 10.1007/S00198-018-4375-2

关键词:

摘要: Is gout a risk factor for future osteoporosis? This large population-based study comprising two matched groups of individuals with and without demonstrates that patients have 20% increase in the developing osteoporosis through an 8-year follow-up. To examine if is associated increased osteoporosis. We conducted nationwide retrospective matched-cohort study. Two cohorts (n = 36,458 71,602 gout) assembled recruited from Longitudinal Health Insurance Dataset containing 1 million subjects. Exclusion criteria were missing data, age < 20 years, short follow-up period, pre-existing Both followed up until incident osteoporosis, death, or end Person-year data incidence rates evaluated. A multivariable Cox model was used to derive adjusted hazard ratio (aHR) after controlling socioeconomic proxy, geographical difference, glucocorticoid allopurinol exposure, various prespecified medical conditions, comorbidities. Men comprised 72.8% cohorts. With 183,729 359,900 person-years non-gout cohorts, 517 811 incidents occurred, respectively, excluding first 3 years The cumulative statistically higher cohort than cohort, at 3.3 versus 2.1% (P = 0.0036, log-rank). Our showed 1.2-fold aHR 1.2 (95% confidence interval, 1.06–1.35). epidemiologic supports hypothesis compared gout; those modest future.

参考文章(33)
Hochberg Mc, Felts Wr, Lawrence Rc, Shulman Le, Medsger Ta, Kelsey Jl, McDuffie Fc, Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. The Journal of Rheumatology. ,vol. 16, pp. 427- 441 ,(1989)
Chang-Fu Kuo, Matthew J. Grainge, Weiya Zhang, Michael Doherty, Global epidemiology of gout: prevalence, incidence and risk factors Nature Reviews Rheumatology. ,vol. 11, pp. 649- 662 ,(2015) , 10.1038/NRRHEUM.2015.91
Elaine M. Dennison, Katrine Hass Rubin, Peter Schwarz, Nicholas C. Harvey, Karen Walker Bone, Cyrus Cooper, Bo Abrahamsen, Is allopurinol use associated with an excess risk of osteoporotic fracture? A National Prescription Registry study Archives of Osteoporosis. ,vol. 10, pp. 36- 36 ,(2015) , 10.1007/S11657-015-0241-4
Seoyoung C Kim, Jun Liu, Daniel H Solomon, Risk of incident atrial fibrillation in gout: a cohort study Annals of the Rheumatic Diseases. ,vol. 75, pp. 1473- 1478 ,(2016) , 10.1136/ANNRHEUMDIS-2015-208161
S. Yang, N. D. Nguyen, J. R. Center, J. A. Eisman, T. V. Nguyen, Association between hypertension and fragility fracture: a longitudinal study Osteoporosis International. ,vol. 25, pp. 97- 103 ,(2014) , 10.1007/S00198-013-2457-8
Victor C Kok, Jorng-Tzong Horng, Hsin-Li Lin, Yu-Ching Chen, Yan-Jun Chen, Kuang Fu Cheng, Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan BMC Cardiovascular Disorders. ,vol. 12, pp. 108- 108 ,(2012) , 10.1186/1471-2261-12-108
Edward Roddy, Hyon K. Choi, Epidemiology of Gout Rheumatic Diseases Clinics of North America. ,vol. 40, pp. 155- 175 ,(2014) , 10.1016/J.RDC.2014.01.001
Jawl-Shan Hwang, Ding-Cheng Chan, Jung-Fu Chen, Tien-Tsai Cheng, Chih-Hsing Wu, Yung-Kuei Soong, Keh-Sung Tsai, Rong-Sen Yang, Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. Journal of Bone and Mineral Metabolism. ,vol. 32, pp. 10- 16 ,(2014) , 10.1007/S00774-013-0495-0
Hein J. E. M. Janssens, Jaap Fransen, Eloy H. van de Lisdonk, Piet L. C. M. van Riel, Chris van Weel, Matthijs Janssen, A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. JAMA Internal Medicine. ,vol. 170, pp. 1120- 1126 ,(2010) , 10.1001/ARCHINTERNMED.2010.196
Victor C. Kok, Hsu-Kai Huang, Tsung-Ming Chao, Ya-Fang Hong, Jorng-Tzong Horng, Regular inhaled corticosteroids in adult-onset asthma and the risk for future cancer: a population-based cohort study with proper person-time analysis Therapeutics and Clinical Risk Management. ,vol. 11, pp. 489- 499 ,(2015) , 10.2147/TCRM.S80793